Dehydroacteoside rejuvenates senescence via TVP23C-CDRT4 regulation

Area of Science:

• Biochemistry
• Cell Biology
• Aging Research

Background:

• Mitochondrial dysfunction and reactive oxygen species (ROS) are key drivers of cellular senescence.
• Current therapeutic strategies for senescence rejuvenation are limited, highlighting the need for novel approaches.

Purpose of the Study:

• To identify natural compounds that can mitigate senescence by targeting mitochondrial ROS.
• To elucidate the molecular mechanisms underlying dehydroacteoside-mediated senescence reversal.

Main Methods:

• Screening of plant-derived phenylpropanoids (PPs) for anti-senescence activity.
• Assessment of mitochondrial function and ROS levels in response to dehydroacteoside treatment.
• RNA sequencing to identify genes involved in the dehydroacteoside pathway.

Main Results:

• Dehydroacteoside was identified as a potent agent that restores mitochondrial function and reduces ROS production.
• Dehydroacteoside treatment reversed senescence-associated phenotypes.
• The gene TVP23C-CDRT4 was found to be critical for dehydroacteoside's effects on ROS reduction and senescence rejuvenation.

Conclusions:

• Dehydroacteoside offers a novel therapeutic strategy for combating senescence by targeting mitochondrial ROS.
• Modulating mitochondrial ROS production presents a promising avenue for developing new anti-aging therapies.